Frontotemporal Lobar Degeneration and MicroRNAs

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Frontotemporal lobar degeneration (FTLD) is a group of neurodegenerative diseases characterized by behavioral and language changes.
• The molecular underpinnings of FTLD remain largely unknown, despite efforts to identify genetic mutations and pathological proteins.
• Emerging evidence suggests a role for RNA metabolism, specifically microRNAs (miRNAs), in FTLD pathogenesis.

Purpose of the Study:

• To review the current understanding of microRNA (miRNA) involvement in the pathogenesis of frontotemporal lobar degeneration (FTLD).
• To explore the potential of miRNAs as diagnostic biomarkers and therapeutic targets for FTLD.
• To discuss the implications of miRNA dysregulation in FTLD-related gene pathways.

Main Methods:

• Literature review of studies investigating microRNAs (miRNAs) in frontotemporal lobar degeneration (FTLD).
• Analysis of research on miRNA regulation of key genes implicated in FTLD, such as progranulin and TMEM106B.
• Synthesis of findings regarding the role of circulating miRNAs in neurodegenerative diseases.

Main Results:

• MicroRNAs (miRNAs) are dysregulated in various neurodegenerative diseases, including FTLD.
• Specific miRNAs (e.g., miR-29b, miR-107, miR-659) are involved in the regulation of the progranulin gene in FTLD.
• The miR-132/212 cluster represses TMEM106B, impacting progranulin levels in FTLD-TDP.

Conclusions:

• MicroRNAs (miRNAs) play a significant role in the pathogenesis of frontotemporal lobar degeneration (FTLD).
• Dysregulated miRNAs present potential as novel biomarkers and therapeutic targets for FTLD.
• Further research into miRNA-based therapies could offer new avenues for treating FTLD.